Clinical Trial Update: Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Infantile-onset Pompe Disease

View source ↗

Summary

This update covers expanded access use of Myozyme (alglucosidase alfa) for infantile-onset Pompe disease and notes marketing approval for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infantile-onset Pompe Disease
• Pompe Disease

Drugs mentioned

• Myozyme (alglucosidase alfa)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Glycogen Storage Disease Type II, Glycogenosis 2 | Status: APPROVED_FOR_MARKETING